We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,300

Open access books available

172,000

International authors and editors

190M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

Sources of Hematopoietic Stem Cells

Piotr Rzepecki, Sylwia Oborska and Krzysztof Gawroński
*BMT Unit, Military Institute of Medicine, Warsaw
 Poland*

1. Introduction

Hematopoietic stem cell transplantation (HSCT) has the potential to cure a variety of malignant and non-malignant diseases. Sources of hematopoietic stem cells for transplantation have expanded progressively since the beginning of the modern era of transplantation in the late 1960s. Although bone marrow was the main source of stem cells in the early years of transplantation, in the past 10 to 15 years peripheral blood has assumed increasing importance. The initial impetus for the use of PBSCs for transplantation was to be able to offer transplantation to patients who were not candidates for the use of bone marrow cells (tumor contamination of the marrow or those with hypocellular marrows). Subsequent studies demonstrated that PBSCs could be mobilized from the bone marrow with either hematopoietic growth factors (GM-CSF, G-CSF) or a combination of chemotherapy and growth factors, which increased the number of hematopoietic progenitors collected from the blood by 10- to 1000- fold compared with steady-state conditions. Umbilical cord blood represents the newest source of stem cells for transplantation. At now peripheral blood is the main source in the autologous setting. Within the allogeneic setting, multiple sources of stem cells are possible and include those derived from individuals related or unrelated to the patient.

Hematopoietic progenitor cell (HPC) products contain hematopoietic stem and lineage-committed progenitor cells capable of providing hematopoietic and immune reconstitution after myeloablative or reduced-intensity preparative regimens. HPCs administered intravenously migrate to the marrow, where they adhere, expand, self-renew (stem cells only), and differentiate. The differentiated cells are released into the blood, restoring blood counts and immunity. The time from administration of HPCs to recovery of adequate or normal blood counts is variable. Recipients of peripheral blood stem cells recover counts faster than recipients of bone marrow. Cord blood tends to be the slowest to engraft.

The minimum number of HPCs necessary for engraftment in a myeloablated recipient has not been established. Different products have widely different numbers of progenitors and stem cells. However, eligibility criteria for some protocols usually dictate a minimum number of cells to be collected and infused.

Several methods are used to measure the number of cells in an HPC collection. Simple cell count may be adequate for many marrow collections. Most centers use flow cytometric enumeration of CD34+ cells for the majority of cellular products. The discovery of the CD34 antigen in the early 1980s revolutionized our understanding of hematopoiesis. Cells expressing CD34 are capable of reconstituting hematopoiesis in lethally irradiated animals and humans, indicating that the putative hematopoietic stem cell expresses CD34.

Fig. 1. Sources of haematopoietic stem cells for different types of transplantation

This type I transmembrane glycoprotein is expressed on:

- 1- 3% of bone marrow mononuclear cells
- 0,01- 0,1% of peripheral blood mononuclear cells
- 0,1- 0,4% of umbilical cord blood cells

2. Marrow as a source of stem cells

Marrow is collected in the day surgery suite using either general or regional anesthesia. With proper fluid and blood replacement, overnight hospitalization should not be required. For the healthy donor, the risks of serious complications from either general or regional anesthesia are about the same. Spinal or epidural anesthesia avoid the nausea that may occur with general anesthesia, especially for young women, but hypotension from loss of vascular tone in the lower extremities often occurs as the volume of marrow is collected. General anesthesia is preferable for the donor with comorbid disorders such as cardiovascular or cerebral vascular disease because of the better control of donor airway and lower risk of hypotension during the harvest procedures. Local anesthesia is acceptable only if a very limited harvest is being performed, as large quantities of lidocaine are cardiotoxic and local anesthesia does not achieve anesthesia of the marrow space. The technique of bone marrow harvest is straightforward and involves repeated aspirations of small volumes (10ml) of marrow. The marrow is removed sterilely from both posterior iliac crests by two operators simultaneously to minimize anesthesia time. Occasionally marrow is obtained from the anterior iliac crest or sternum. Typically we do two puncture through the skin and multiple bone punctures. Do not take more than 25 ml of bone marrow per kilogram of donor - this is the upper limit on the volume of collected bone marrow. The marrow is placed in a sterile container with an electrolyte solution and an appropriate anticoagulant.

The cell suspension is passed through sterile filters to remove fat, bone particles, and cellular debris [4,5]. For patients with a history of radiation or tumor involvement of one pelvic crest, adequate cells can be harvested from the anterior and posterior crests of the other side [6-8].

2.1 Toxicity and adverse events associated with bone marrow collection

Anesthesia complications present the major health risk to the donor. Marrow aspiration is generally well tolerated. Major complications occur in approximately 0.27% of healthy allogeneic donors and up to 0.97% of autologous transplant patients [9-10]. Complications include hemorrhage and infections at skin puncture sites. Severe hematomas and neuralgias rarely occur, but attention to pelvic anatomy is required to decrease the risk of damage to vessels and nerves lying under or adjacent to the iliac crest harvest sites. Irritation of the sacral nerves may result from needle penetration through the pelvic bone or from blood tracking into the nerve roots and requires several months of convalescence. Localized pain is common, may last for several days, and may require a brief period of medication with opioid/acetaminophen combinations [4]. In a survey of almost 500 donors for unrelated marrow transplantation, the average time for recovery was 15.8 days, although 10% of donors required more than 30 days for self-reported complete recovery [11]. Most donors are able to return to routine activities 1 to 2 days after harvesting. In a study of related donors, an equivalent level of pain was reported by donors undergoing bone marrow harvesting and those receiving filgrastim for mobilization of PBSC [12]. Minor complications occur in 6-20% of marrow donations [11]. These include such events as hypotension, syncope, severe post-spinal headache, excess pain, unexpected hospitalization and minor

Symptom	Women %	Men %
Tired	85	76
Collection site pain	78	75
Back pain	67	68
Nausea	63	40
Sore throat	62	57
Pain sitting	62	57
Lightheadedness	53	42
Headache	40	32
Vomiting	39	17
Intravenous site pain	37	23
Fever	22	22
Bandage pain	19	26
Bleeding at site	10	8
Fainting	7	5

Table 1. Symptoms reported by National Marrow Donor Program (NMDP) bone marrow donors, 1987-2000 (n=9601) [8]

infections. In National Marrow Donor Program (NMDP) observation the frequency of serious adverse events following marrow donation is estimated at 0,1-0,3%. Reactions to the anesthetic agents administered may be adverse reactions, hypersensitivity or idiosyncratic reactions. One NMDP donor experienced laryngospasm following extubation. Additionally, several NMDP donors have experienced profound bradycardia during anesthesia, including regional anesthesia (spinal and epidural), that required emergency treatment. Death has occurred among normal marrow donors. A recent review of 7857 marrow collections reported two deaths [13].

2.2 Quantity of bone marrow cells for transplantation

Generally, 10-20ml marrow/kg of donor weight is harvested to achieve a minimum mononuclear cell (MNC) count of 2×10^8 to 8×10^8 MNC/kg of recipient body weight, although ideally up to $4,0 \times 10^8$ to 8×10^8 MNC/kg is preferred to compensate for cell loss during processing and to ensure adequate engraftment. The only setting in which higher numbers of MNC/kg definitely have been shown to be of benefit is aplastic anemia, in which low cell counts have been associated with an increased risk of rejection. Marrow contains mature red cells, white cells, platelets, mast cells, fat cells, plasma cells, committed progenitors of all lineages and hematopoietic stem cells. The most common modifications of allogeneic marrow are to decrease the volume of ABO-incompatible red cells, remove ABO- incompatible plasma, isolate CD34+ cells and remove donor T lymphocytes. The most common modification of autologous marrow is to reduce the volume by removing plasma and red cells before cryopreservation [4].

2.3 “Rich” bone marrow

Pretreatment of the marrow donor with filgrastim (granulocyte- colony-stimulating factor G-CSF) may increase the number of myeloid progenitor cells harvested and decrease the period of posttransplant aplasia to that achievable by PBSC transplantation [14]. Hematologic recovery in patients who are treated with autologous stem cells taken from bone marrow after G-CSF stimulation (rich bone marrow – RBM) is faster than in patients without G-CSF. In the Polish study [15] were estimated engraftment outcomes of patients who received bone marrow unstimulated or stimulated with G-CSF. The median and range for neutrophil engraftment times in this study when they used stimulated bone marrow were comparable with those published by Lemoli et al. [16]. It seems that a better method of obtaining stem cells from bone marrow is the RBM. Using of stimulated bone marrow can faster engraftment comparing to non-stimulated bone marrow and can help patients, who fail to collect adequate number of stem cells from their peripheral blood. It is generally accepted that RBM engraft more rapidly than unstimulated bone marrow and that RBM appear to have similar engraftment times to peripheral blood stem cell transplantations suggesting that it is prior G-CSF exposure, not the anatomic site, which influences engraftment [14,17,18]. CD34+ cell dose now is being correlated with transplant outcomes, with more rapid engraftment kinetics, possibly lower transplant-related mortality, and better overall survival, for example, in recipients of allogeneic products containing higher quantities of CD34+ cells. Otherwise patients receiving filgrastim- primed bone marrow had significantly less steroid-refractory acute graft-vs-host disease (GvHD), less chronic GvHD and fewer days of immunosuppressive therapy. Download stimulated bone marrow may

favor the acquisition of more hematopoietic cells and facilitate reconstitution after myeloablative therapy with no significant increase in risk of GvHD [19].

	PLT> 20	ANC> 0.5 G/L	Length of hospitalization
Median time to recovery (RBM)	12,6 days	13,0 days	17,3
Median time to recovery (bone marrow without stimulation of G-CSF)	18,8 days	17,8 days	23,1

Table 2. Time to recovery of platelets (PLT) and neutrophils (ANC) and length of hospitalization when we used bone marrow after stimulation G-CSF and without stimulation of G-CSF [15]

3. Peripheral blood stem cells (PBSC)

Stem cells were detected in the peripheral blood of mice in 1962 and in human in 1971 [20]. However, interest in peripheral blood stem cell transplantation did not develop until mid-1980s. During 1985-1986 several centers from different parts of the world reported encouraging results of the autologous transplants using hematopoietic progenitor cells collected from peripheral blood [21,22]. The first allogeneic transplant with peripheral blood progenitor cells was reported in 1989 [23]. Use of PBSC became more common after 1995 with the publication reports of successful allogeneic transplants with PBSC [24-26]. By stimulating the donor with either hematopoietic growth factors, or chemotherapy and growth factors, a sufficient number of circulating stem cells for marrow rescue can be collected in one to three apheresis procedures. Mobilized PBSC products are routinely used as an alternative source of HSCs for transplantation [27,28]. A PBSC collection is performed with a cell separation device originally developed for therapeutic leukapheresis, plasmapheresis and platelet donation procedures. This apheresis device uses a centrifuge to separate and collect mononuclear cells, including HSCs, from the blood. In order to achieve an adequate HSCs for transplantation it is necessary to process 12 to 25 liters of blood or 2.5 to 6.0 times the patient's/ healthy donor's calculated blood volume. Investigators have reported that the yield of CD34+ cells increases continuously as more blood volumes are processed. Although up to six times the donor's blood volume can be safety processed, some donors are not able to tolerate 4 or 6 hours being connected to an apheresis machine. Therefore, these donors require repeated collections on sequential days once the peripheral CD34+ count has increased to acceptable levels (>10 CD34+ cells/μl) for collection. There are currently three different commercially available apheresis instruments. In each case, instrument settings such as inlet flow rate, centrifuge speed, collect pump flow rate and anticoagulant: whole blood ratio vary, depending on the target cell type to be collected. The three instruments operate differently. The Amicus (Baxter) and the COM.TEC (Fresenius) are more automated, computer-controlled instruments; however, the Spectra is more widely used [1,29]. Because an apheresis procedure is used to collect PBSC products, they contain very few erythrocytes or granulocytes, compared to marrow, and are primarily composed of mononuclear cells (MNCs). PBSC products also contain larger numbers of HPCs than either marrow or cord blood, and therefore facilitate faster engraftment and shorter hospital stays.

Patients who have been heavily pretreated with multiple rounds of chemotherapy or radiation therapy often mobilize poorly and require multiple collection episodes [30].

Although the peripheral blood of healthy individuals contains fewer than 0,1% HSCs, this number increases dramatically during recovery from cytotoxic therapy and even more so more so then recombinant CSFs such as G-CSF are administered. Various mobilizing techniques are used by centers and generally consist of growth factor administration alone or in combination with various types of chemotherapy. G-CSF and high-dose cyclophosphamide (CY) are the most commonly used agents [28, 31-33]. Currently, almost all of autologous and a majority of allogeneic transplants are performed with PBSC. Advantages of PBSC over bone marrow include [21,34]:

- Elimination of the need of general anesthesia, pain and other side effects of bone marrow aspiration.
- Patients with bone marrow metastases could be transplanted with autologous PBSC as there is a potential for tumor cell free collection.
- The hematological recovery with PBSC was faster than bone marrow significantly reducing the time to transfusion independence.

PBSC products contain larger numbers of T cells than marrow collections, and thus present a greater risk of causing graft-versus-host disease (GvHD) in the allogeneic setting, although the rate of acute GvHD is less than originally feared [35-39]. In a prospective randomized study comparing PBSC donation with bone marrow, PBSC products contained double the number of CD34+ cells, eight fold more of T and NK cells than bone marrow collection. The advantages to the recipient were faster recovery of both neutrophil and platelets with PBSC compared to marrow without increasing risk of graft-vs-host disease. Another multi-center study also reported faster neutrophil and platelet recovery but significantly more frequent acute and chronic GvHD in PBSC recipients than recipients of bone marrow cells. There were no significant differences in transplant related mortality, relapse rate and overall survival were found [40-42].

3.1 Mobilization regimens

Recent advances in stem cell mobilization techniques have exploited the interactions between stem cells and the bone marrow microenvironment. Composed of stromal cells, endothelial cells, osteoblasts and other matrix components (collagens, fibronectins, proteoglycans), the bone marrow microenvironment anchors hematopoietic stem cells through a wide range of adhesive interactions [43]. Hematopoietic stem cells express a broad array of cell surface receptors, namely the adhesion molecules lymphocyte function-associated Ag-1, very late Ag-4, and Mac-1; the chemokine receptors CXCR4 and CXCR2; the cell surface glycoproteins CD44 and CD62L; and the tyrosine kinase receptor c-kit [43-45]. The bone marrow stroma contains stromal cell-derived factor-1 (SDF-1), CXC chemokine GRO- β , vascular cell adhesion molecule-1, kit-ligand, P-selectin glycoprotein ligand-1 and hyaluronic acid, all of which are cognate ligands for the stem cell adhesion molecules [43-45]. Data from a number of preclinical models showed that inhibition of these receptor-ligand interactions resulted in enhanced progenitor cell mobilization [46-48].

Several exogenous hematopoietic cytokines that can mobilize hematopoietic progenitor cells into circulation are now available. Granulocyte colony stimulating factor (G-CSF) (filgrastim, lenograstim, pegfilgrastim) and granulocyte macrophage colony stimulating factor (GM-CSF) (sargramostim) are most commonly used for mobilization. They are used

	G-CSF	GM-CSF	Erythropoietin	Plerixafor
Adhesion factors	↓	Additive effects with G-CSF. May inhibit osteoclast activation.	Exact mechanism unknown, but additive when used in combination with G-CSF or GM-CSF	
CXCR4	↓ or ↑			No effect or ↓
SDF-1	↓			
MMPs	↑			
Neutrophil elastase	↑			

MMP- matrix metalloproteinase; SDF-1: stromal-derived factor 1α

Table 3. Factors using for mobilization- mechanism of action [31]

alone to mobilize hematopoietic stem cells into circulation in healthy donors for allogeneic transplantation and in patients who are in complete remission or in heavily pretreated ones for autologous transplantation. Approximately 4 days after the daily administration of G-CSF at a dose of 8-20 mcg/kg body weight, there is an increase in the number of CD34+ cells in the blood of patients and healthy stem cell donors. With this method, the progenitor cell peak is reached between days 5 and 6 [49]. The extent of mobilization is determined by the age of the patient, the diagnosis, the earlier cytotoxic therapy, the dose of G-CSF and the sequence of G-CSF administration [50]. Kroger et al [51] showed that mobilization was more effective if the total dose of G-CSF was divided into two equal fractions and given in the morning and in the evening rather than as a single dose once daily. G-CSF administered every 12 h at doses of 5 µg/kg provides better CD34+ cell yield than 10 µg/kg once a day in normal donors which may translate into a decrease in the number of apheresis required to obtain enough numbers of CD34+ cells for allogeneic PBSC transplant.

3.2 Which growth factor should we choose?

Filgrastim is commonly used to mobilize peripheral blood stem cells. Pegylation of filgrastim (pegfilgrastim) leads to prolongation of its half- life without loss of activity. Attachment of the polyethylene glycol (PEG) moiety reduces renal excretion and masks proteolytic cleavage sites resulting in elevated G-CSF serum levels for up to 14 days after a single injection. While filgrastim is also cleared by the kidneys, pegfilgrastim is mainly eliminated via a neutrophil-mediated clearance mechanism [52-54]. The initial results of using pegfilgrastim obtained in limited numbers of patients with solid tumours showed that pegylated G-CSF was principally capable of mobilizing haematopoietic progenitor cells [54]. In 2001 and 2003, two studies were designed for the treatment of myeloma patients. The treatment regimens were comparable and employed DT-PACE [55,56] as mobilization chemotherapy. In the first study patients received twice a day filgrastim, until completion of stem cell collection; in the second study two doses of pegfilgrastim were administered after DT-PACE. After a cycle of DT-PACE, pegfilgrastim 6 mg was given subcutaneously on days

+6 and +13. If the WBC count $> 100 \text{ G/l}$ by day +13 the second dose of pegfilgrastim was not administered. Investigators found some advantages when pegfilgrastim was used:

- A higher percentage of patients collected $15 \times 10^6/\text{kg}$ in the first three days ($p < 0.001$)
- The median number of CD34 cells/kg collected on day 1 was higher ($p = 0.004$)
- The median number of growth factor injections was 2 versus 26 ($p < 0.0001$)
- Post-transplantation neutrophil recovery was faster after first and second transplant ($p < 0.001$)
- Platelet recovery was faster after first transplant (when less stem cells were infused) ($p = 0.01$)
- Authors concluded, that pegfilgrastim may be considered the standard of care for stem cell mobilization.

Kobbe et al. [54] found that in patients with multiple myeloma, a single dose of 6 mg pegfilgrastim after cyclophosphamide ($4\text{g}/\text{m}^2$) is equally effective in terms of the mobilization of haematopoietic progenitor cells as daily administration of conventional G-CSF. There is no increase in this effect if the dose is doubled to 12 mg. This finding is consistent with the results of a recently published, blinded, placebo-controlled multicenter study conducted in patients with malignant lymphomas [57]. These results were also confirmed by other groups of investigators [58,59]. There are no studies on the use of pegfilgrastim to mobilize haematopoietic stem cells in patients with acute leukemia. Pegylated G-CSF has not also been studied in the so-called "poor mobilizers".

Two formulations of recombinant human (rh) G-CSF, one glycosylated form and one non-glycosylated, are available. The glycosylated form, lenograstim, possesses at least 25% greater bioactivity *in vitro*. Some comparative studies into the preparation's potential to mobilize haematopoietic stem cells were performed to assess the potential greater efficacy of lenograstim *in vivo*. Ataergin S et al. [60] investigated whether a 25% reduced dose of lenograstim at $7.5 \mu\text{g}/\text{kg}/\text{day}$ is equivalent to $10 \mu\text{g}/\text{kg}/\text{day}$ filgrastim for autologous peripheral blood stem cell mobilization and transplantation. The two evaluated patients' cohorts were similar in regard to disease, sex, body, weight, body surface area, conditioning regimens, previous chemotherapy cycles and radiotherapy. Each growth factor was administered for 4 consecutive days. The first PBSC apheresis was done on the 5th day. In the posttransplant period, the same G-CSF was given at $5 \mu\text{g}/\text{kg}/\text{day}$ until leukocyte engraftment. No significant difference was seen in the median number of CD34+ cells mobilized, as well as the median number of apheresis, median volume of apheresis, percentage of CD34+ cells, and CD34+ cell number. Leukocyte and platelet engraftments, the number of days requiring G-CSF and parenteral antibiotics, the number of transfusions were similar in both groups in the posttransplant period. In conclusion, lenograstim $7.5 \mu\text{g}/\text{kg}/\text{day}$ is as efficacious as filgrastim $10 \mu\text{g}/\text{kg}/\text{day}$ for autologous PBSC mobilization and transplantation.

Another study [61] explored the efficacy of the IGEV regimen (ifosfamide, gemcytabine, vinoreblin and prednisone) combined with a fixed dose of lenograstim ($263 \mu\text{g}/\text{day}$) to mobilize PBSCs in 90 Hodgkin's lymphoma patients. An adequate number of CD34+ cells ($> 3 \times 10^6/\text{kg}$) were collected in 98,7% mobilized patients. Hematological and non-hematological side effects were acceptable, and no toxic deaths occurred. These results confirm that the IGEV regimen with lenograstim support can be used successfully and safely to mobilize PBSCs.

Kopf B et al.[62], in 2006 conducted a prospective randomized clinical trial to assess the mobilizing efficacy of filgrastim, lenograstim and molgramostim (GM-CSF) following a disease-specific chemotherapy regimen. In conclusion, all three growth factors were efficacious in mobilizing peripheral blood progenitor cells with no statistically significant difference between CD34+ cell yield and the different regimens, and the time to apheresis is likely confounded by the different mobilization regimens. An advantage on platelet recovery with molgramostim, suggested by other authors [63,64] was not confirmed by results of this study.

3.3 G-CSF in conjunction with chemotherapy

Growth factor combined with chemotherapy are given for patients, who are candidates to autologous transplantation and need additional treatment as debulking therapy or to achieve complete/ partial remission before transplantation [65]. A variety of chemotherapeutic agents are used with G-CSF or GM-CSF to mobilize hematopoietic stem cells for autologous transplantation. Administration of CY with G-CSF is widespread, as this regimen mobilizes hematopoietic stem cells effectively and is highly active against tumor cells [65]. Successful chemomobilization regimens used in combination with G-CSF are often disease oriented. Some of the most frequently used chemotherapeutic regimens in lymphoma patients include IEV (ifosfamide, epirubicin and etoposide), DHAP and ESHAP (etoposide, Ara-C, methylprednisolone and cisplatin) [66,67]. Patients with other hematologic malignancies are frequently treated with ICE (ifosfamide, carboplatin and etoposide) plus G-CSF for mobilization [68].

Chemomobilization is widely used in clinical practice because the addition of a myelosuppressive chemotherapy agent to a cytokine mobilization regimen results in higher CD34+ cell yields, which may promise better outcomes for patients. In particular, mobilization with CY and G-CSF rather than with G-CSF alone improves CD34+ cell collection significantly in patients with either MM [69,70] or NHL [71,72]. However, it has been noted that the use of CY plus G-CSF severely depletes T cells and spares regulatory T cells, which could negatively affect immune reconstitution [73]. The benefits of adding chemotherapeutic agents to a G-CSF mobilization regimen may be offset by the increased risk of complications to the patients. Compared with mobilization regimens using G-CSF alone, chemomobilization is associated with increased morbidity, greater risk of infection, more hospital admissions, transfusions, antibiotic therapy and considerably greater cost overall. [28]. Although treatment-related mortality is rare, significant morbidity related to neutropenia that can often require hospitalization has been described, and many reports point to greater resource utilization with chemomobilization than with cytokine-alone mobilization [28].

Koumakis et al [74] compared various time schedules of granulocyte colony-stimulating factor (G-CSF) treatment in a clinical model of patients who received high-dose cyclophosphamide (4.5 g/m²). They found, that:

- G-CSF administration after high-dose cyclophosphamide has a similar effect upon the incidence and duration of severe leukopenia and thrombocytopenia
- Severe leukopenia is shorter when G-CSF starts up to 72 hours after high-dose of cyclophosphamide
- The length of G-CSF administration and its cost is also in favor of early initiation of treatment as well as the number of febrile days and antibiotic use

- Delayed (> 72 hours) or supportive treatment indicate more febrile days, antibiotic use and higher cost when compared to the early groups

For these reasons, preemptive rather than therapeutic administration of G-CSF is indicated in patients who receive high-dose cyclophosphamide as treatment for mobilization CD34+ cells into peripheral blood.

3.4 Toxicity of growth factors

Cytokine-mobilized PBSC collected from healthy sibling or unrelated donors are increasingly used as stem-cell source in the allogeneic setting. PBSCs have been shown to be superior to BM-derived stem cells during the early posttransplant course. The high CD34+ cell yield in PBSC grafts significantly shortens the posttransplant aplasia and the need for blood component support, especially platelets [40,41]. Both cytokine administration and harvest procedure cause unphysiological conditions in healthy individuals. The effects of rhG-CSF on peripheral blood count and leukocyte function, cytokine release and response, coagulation parameters and metabolic changes have been reviewed by Anderlini et al [75,76]. Limited data exist on the late effects of cytokine mobilization and PBSC collection. Until now, there is no convincing evidence that rhG-CSF administration leads to an increased risk to develop hematological malignancies in healthy individuals [77]. Leitner GC et al [78] investigated the actual quality of life (QoL) and health status of the donors as well as the need for medical treatment since PBSC donation by a questionnaire (151 donors were evaluated). The questionnaire was sent to donors at a median of 4 (range: 0.2-11) years after donation. rhG-CSF mobilization as well as subsequent PBSC collection is shown to be well tolerated in the short- and long-term profiles in these sibling donors. It had no negative influence on health status and QoL in the majority of them. Investigators observed no increased risk for hematological or oncological disorders. However, to acquire profound knowledge about rhG-CSF- and donation-related long term risks, consecutive monitoring of more donors for at least 10 years has to be performed. Hasenclever and Sextro [79] stated that to exclude or to show a 10-fold increase in the 10-year cancer incidence, a long-term prospective follow-up of several thousand donors for at least 10 years would be necessary. In 2009 the report from European Group for Blood and Marrow Transplantation Group was published [80]. Three hundred and thirty-eight allogeneic transplant teams from 35 European countries were asked to report numbers of fatalities, severe adverse events and hematologic malignancies occurring among their hematopoietic stem cell donors. 51024 first allogeneic hematopoietic stem cell transplantations were evaluated, of which 27770 were bone marrow and 23254 peripheral blood. They observed five donor fatalities, one after a bone marrow donation and four after peripheral blood donation (incidence 0.98 per 10000 donations; 95% CI 0.32-2.29), 37 severe adverse events (7.25/10000; 95% CI 5.11-9.99), of which 12 in bone marrow donors (4.32/10000; 95% CI 2.24-7.75) and 25 in peripheral blood donors (10.76/10000; 95% CI 6.97-15.85; $p < 0.05$) and 20 hematologic malignancies (3.92/10000; 95% CI 2.39-6.05), of which 8 after donating bone marrow and 12 after donating peripheral blood stem cells. The observed incidence rate of hematologic malignancies did not exceed the expected incidence in an age- and sex-adjusted general population. Authors concluded, that hematopoietic stem cell donation is associated with a small but define risk of fatalities and serious adverse events. True incidences might be higher, due to potential underreporting by study design. A continuous, standardized donor follow-up is needed to define donor risk groups and to monitor intermediate and long-term sequelae.

Healthy donors who were mobilized using lenograstim and who were undergoing peripheral hematopoietic cell collection with apheresis were enrolled in a surveillance protocol. The study was conducted by Martino et al [81]. The median dose of lenograstim was 10 µg/kg (range 5-15). 184 healthy donors have been assessed with a median follow-up of 62 months (range 2-155). The short-term adverse events:

- Bone pain 71,2%
- Headache 27,7%
- Insomnia 22,3%
- Fatigue 19,0%
- Nausea 12,0%
- Fever 5,4%
- Increased spleen size 4,3%

No vascular disorders, no cardiac disease
Long-term follow-up included monitoring of adverse events, neoplastic disease or other pathologies:

Type of adverse event	Number of donors suffered from	Time of occurrence after donation [months]
Transit ischaemic attack	1	39
Ankylosing spondylitis	1	28
Secondary polyglobulia	1	50
Lung cancer	1	19
No haematological disease was observed		

During hematopoietic stem cell mobilization in healthy donors, slight thrombocytopenia is common and is attributed to the leukapheresis procedure or to splenomegaly. The platelet depletion is a recognized effect of continuous flow leukapheresis, particularly large-volume leukapheresis [75].

About one-third of neutropenic patients chronically treated with rh-G-CSF develop palpable splenomegaly and there have been reports of spontaneous spleen rupture in rhG-CSF or cyclophosphamide plus rh G-CSF- mobilized individuals or even in patients treated with rhG-CSF or rhGM-CSF after chemotherapy for acute leukemia or lymphoma. Few data are available on changes in spleen size as a result of a brief course of rhG-CSF [82]. Picardi et al. evaluated spleen size, comparing palpation with ultrasound (US)-evaluated longitudinal diameter and volume, in 13 healthy donors and 22 patients with a hematological malignancy who were undergoing PBSC mobilization with rhG-CSF-including regimens. When evaluated by sensitive methods, rhG-CSF caused spleen enlargement in almost all individuals treated. US-calculated volume proved to be an excellent method, much better than longitudinal diameter, for detecting non-palpable splenomegaly induced by rhG-CSF [83].

G-CSF has been also discussed as the causative agent for the occurrence of [84-94]:

- Sweet syndrome
- Leukocytoclastic vasculitis
- Interstitial pneumonitis
- Adult respiratory distress syndrome (ARDS)
- Pyoderma gangraenosum

- Capillary leakage
- Stroke
- Acute gouty arthritis
- Iritis
- Severe anaphylactoid reactions
- Non-traumatic rupture of the spleen
- Severe pyogenic infection (painful perianal abscess and apical abscess)

3.5 How can we predict the optimal time for adequate collection of peripheral blood progenitor cells after chemotherapy ?

The absolute number of circulating CD34+ cells was found to correlate closely with the CD34+ cell yield of the corresponding leucapheresis product. The number of CD34+ cells circulating in the peripheral blood reliably predicts both:

- The number of CD34+ cells
- The number of CFU-GM harvested

By monitoring the level of circulating CD34+ cells during the mobilization period, generally starting at about day 9 or 10, the day to perform the leucapheresis can be planned. The optimal time for collecting PBSC is when a peripheral blood sample contains at least 20×10^3 circulating CD34 cells/ml. This value provided at least 2×10^6 CD34+ cells/kg in a single leucapheresis, harvested the following day, in 94% of the collections regardless of the patient's diagnosis or mobilization regimen [95]. In Hill's study [96] a total of 168 adult patients with haematological malignancy were primed using low-moderate dose cyclophosphamide ($1.5-3 \text{ g/m}^2$) with G-CSF $5-10 \text{ } \mu\text{g/kg}$ per day. Harvesting was booked and peripheral blood counts first checked between 6 and 10 days post-priming. The peripheral blood CD34+ cell count correlated significantly with harvest yield ($r = 0.8448$, $p < 0.0001$). A peripheral blood CD34+ count $\geq 10 / \mu\text{l}$ predicted a collection of $\geq 2 \times 10^6 / \text{kg}$ (positive-predictive value of 61%, negative-predictive value 100%). There was no benefit to checking the peripheral blood CD34+ count or booking apheresis before day 9 post-cyclophosphamide.

3.6 What is the minimal CD34+ cells threshold collected from peripheral blood for sufficient engraftment?

What is the optimal CD34+ cells number for transplantation?

Gandhi et al. [97] advocated a minimum CD34+ threshold of $> 1.0 \times 10^6 / \text{kg}$ in patients without extensive prior chemoradiotherapy, and $\geq 2.0 \times 10^6 / \text{kg}$ in all other patients. In this study all patients infused with grafts containing CD34+ cell doses between 1.0 and $2.0 \times 10^6 / \text{kg}$ engrafted by day 51. The only variable associated with slow platelet recovery was exposure to stem cell toxins (BCNU, melphalan, CCNU and mustine). The majority of patients with CD34+ $> 1.0 \times 10^6 / \text{kg}$ achieved rapid and sustained engraftment and the only predictive factor of delayed recovery is prior exposure to stem cell toxins.

Villalon et al. [98] analyzed the factors affecting mobilization and engraftment in autologous peripheral blood progenitor cell transplantation according to the number of CD34+ re-infused ($< 2.0 \times 10^6 / \text{kg}$ CD34+ vs $> 2.0 \times 10^6 / \text{kg}$ CD34+). They found that,:

- Neutrophil and platelet engraftment was significantly longer with $< 2.0 \times 10^6 / \text{kg}$ (12 vs 10 days, $p = 0.014$ and 16 vs 13 days, $p = 0.0001$ respectively)

- Platelet recovery was affected by exposure to alkylating agents ($p = 0.04$), refractory disease ($p = 0.02$), and AML ($p = 0.0001$), but only the last two variables remained significant in Cox regression ($p < 0.01$)
- Granulocyte engraftment was longer in CML (univariate, $p = 0.04$) and in refractory disease (multivariate, $p = 0.02$)
- In patients re-infused with $> 2.0 \times 10^6/\text{CD}34+/\text{kg}$, the Cox model did not identify prognostic factors for haematopoietic recovery

They concluded, that although mobilization schedules and disease status influenced not only the yield of progenitor cells, but also the engraftment kinetics, the number of CD34+ re-infused was the main predictor of hematopoietic recovery. While engraftment succeeded in most of the cases, the re-infusion of $> 2.0 \times 10^6/\text{kg}$ resulted in significantly shorter recovery times. Thus, for autologous stem cell transplantation, it is common practice to infuse at least $2.0 \times 10^6/\text{CD}34+/\text{kg}$ to ensure rapid engraftment. But investigators [99-102] found, that when comparing patients receiving at least $5 \times 10^6/\text{kg}$ and $2-5 \times 10^6/\text{kg}$ CD34+ cells there are:

- A significant reduction in the median number of days with fever
- Incidence of fever
- Duration of antibiotic treatment
- Faster neutrophil recovery

There was no significant difference in the number of platelet or red cell transfusions

Thus, transplantations with stem cell dose of at least $5.0 \times 10^6/\text{kg}$ reduce infectious complications and should thereby increase the safety of this type of therapy while reducing duration (and cost) of antibiotic therapy.

In Bolwell study [103] investigators checked whether patients collecting high numbers of CD34+ cells ("super mobilizers") have a better outcome than other patients. Super mobilizers were defined as collecting a minimum of $8.0 \times 10^6/\text{CD}34+/\text{kg}$. In this study super mobilizers were younger and more likely to have received two or fewer prior chemotherapy regimens. Median CD34+ cell dose for the super mobilizing group was 13.7×10^6 CD34+ /kg versus 4.4×10^6 CD34+ /kg in the standard collecting group. The super mobilizer group had a superior overall survival ($p = 0.006$). In multivariable analysis, favorable disease status and younger age at transplant, and super mobilization were associated with improved survival.

It is reasonable to believe that the CD34+ cell dose has a positive influence on engraftment and survival. But, when compared with BM, PBSC grafts contain significantly more nucleated cells, more CD34+ hematopoietic stem cells, and more CD3+ lymphocytes [104,105]. It has been shown that granulocyte colony-stimulating factor (G-CSF)-mobilized CD34+ hematopoietic stem cells not only participate in engraftment, but also have an immunogenic role [106-108]. In the setting of T-cell-depleted allogeneic transplants using CD34+ positive selection as T-cell-depletion method, Urbano-Ispizua et al [109] could show that a high CD34+ cell dose not only does not improve the clinical results, but also actually may be associated with a poorer outcome. There is the suggestion, that transplantation with a higher CD34+ cell dose was detrimental in terms of chronic GvHD in allogeneic CD34+ cell-selected peripheral blood stem cell transplantation. Moreover, this association may also exist in the context of allogeneic unmanipulated PBSC where a higher T-cell content or extremely high dose of CD34+ cells can be involved. It should be noted that CD34+ cells not only participate in engraftment, but also have an immunogenic role. However, although

cGvHD is a leading cause of late mortality in allogeneic settings, it also plays a positive role in preventing relapse, especially in advanced hematological malignancies with a high risk of relapse [110]. Sohn et al [111] investigated the impact of the CD34+ cell dose on chronic graft-versus-host disease and the clinical outcome in adult patients submitted to allogeneic peripheral blood stem cell transplantation from HLA-identical siblings. The patients were classified into “low” or “high” CD34+ cell dose groups based on whether they received less or more than a median CD34+ cell dose of $10.5 \times 10^6/\text{kg}$, respectively. There was a significant difference in the incidence of extensive cGvHD and relapse between the two groups. With a median follow up of 335 days, the 3-year survival estimate for whole population was 47.9%, while that for the low and high groups was 29.9 and 67.8% respectively ($p = 0.0434$). An inverse relation was noted between the relapse rate and the incidence of extensive cGvHD ($p = 0.043$). Authors concluded, that it would appear reasonable that the optimal dose of CD34+ cells should be determined based on the disease status or aggressiveness of the malignant cells in each patient. Thus, in the case of patients with a high risk of relapse, transplantation with a CD34+ cell dose $> 10.5 \times 10^6/\text{kg}$ would seem to be acceptable to minimize the risk of relapse. Mohty et al [110], Sohn et al [111] investigated whether there was a correlation between the composition of PBSC grafts (CD34+ and CD3+ cells) and hematological recovery, GvHD, relapse and relapse-free survival after myeloablative HLA-identical sibling PBSCT. Neither hematological recovery, acute or chronic GvHD, nor relapse, was significantly associated with CD3+ cell dose. Increasing CD34+ stem cells was associated with faster neutrophil and platelet recovery. The probability of extensive cGvHD at 4 years was 34% in patients receiving a “low” CD34+ cell dose ($< 8.3 \times 10^6/\text{kg}$) as compared to 62% in patients receiving a “high” CD34+ cell dose ($> 8.3 \times 10^6/\text{kg}$) ($p = 0.01$). At a median follow-up of 59 months, this has not translated into a difference in relapse. In patients evaluable for cGvHD relapse free survival was significantly higher in patients receiving “low” CD34+ cell dose as compared to those receiving a “high” CD34+ cell dose ($p = 0.04$). This difference was mainly because of a significantly higher cGvHD-associated mortality ($p = 0.01$).

3.7 Factors to predict the efficiency of blood progenitor cell mobilization

It is important to note that most patients mobilize adequate numbers of CD34+ cells using a regimen of G-CSF alone. Although the addition of chemotherapy improves CD34+ yield, this comes at the expense of increased short-term toxicity and, possibly, the increased risk of secondary myelodysplastic syndrome [112]. Even with chemotherapy-growth factor combination regimens, it may be difficult to achieve an adequate CD34+ cell yield in some patients. Several studies have identified predictors of poor PBSC yield.

- The most important factor is the amount of myelosuppressive therapy (chemotherapy +/- radiation therapy) received prior to mobilization
- Using stem cell toxic agents prior to mobilization: nitrogen mustard, procarbazine, melphalan, carmustine and $> 7.5 \text{ g}$ of cyclophosphamide
- The number of chemotherapeutic regimens > 6 and ≥ 11
- Duration of exposure to chemotherapy (> 12 months)
- Short time interval since last chemotherapy < 6 months and < 65 days
- Previous radiation therapy
- Hypocellular marrow
- Refractory disease

A recent scoring system based on previous therapy may be useful in predicting CD34-positive cell yield.

Treatment score was built by Drake et al [113], and then improved by others [114,115]. Treatment score was evaluated (as given in detail by Drake et al) [113] by Clark [114]. There was one except in Clark study, in addition, arbitrarily allocated a score of 2 for ifosfamide per treatment cycle.

Briefly, chemotherapy drugs are assigned a toxicity factor as follows:

- 0. prednisolone, dexamethasone;
- 1. vincristine, vinblastine, bleomycin, alpha interferon;
- 2. cyclophosphamide, anthracyclines, cisplatin, etoposide, ifosfamide;
- 3. chlorambucil, procarbazine;
- 4. melphalan, carmustine, mechlorethamine, lomustine.

The number of courses of each drug received was multiplied by its toxicity factor, and the score for each drug administered was summed to yield an overall treatment score. An additional 2 points were added if mediastinal radiotherapy was administered. In this study was validated this scoring system on an independent group of 99 patients undergoing 103 harvesting episodes. In 61 patients mobilized with cyclophosphamide 1.5 g/m² and G-CSF, those with treatment scores less than 21 yielded significantly more CD34-positive cells than patients with scores greater than 63 (*P* = 0.0012). Previous treatment with melphalan or carmustine was associated with a significantly lower yield of CD34-positive cells (*P* = 0.0001). No relationship was seen between the time from previous chemoradiotherapy and harvest outcome. Patients with treatment scores less than 21 required a shorter duration of G-CSF therapy (*P* = 0.05). Similar findings were seen in 42 further mobilization cycles undertaken with alternative mobilization schedules. The data suggest that a score summarizing previous treatment can be used to predict CD34 yields, and could be of clinical use to identify poor PBPC mobilisers in advance. The next improvement in scoring system was done by Jantunen et al. [115]. Results are shown in the table.

0	Prednisolone, dexamethasone, METHYLPREDNISOLONE
1	Vincristine, vinblastine, bleomycin, METHOTREXATE, alpha-interferon, CYTOSINE ARABINOSIDE
2	MITOGUAZON, cyclophosphamide, IFOSFAMIDE, cisplatin, anthracyclines, MITOXANTRONE, etoposide
3	Chlorambucil ^a , procarbazine, FLUDARABINE, DACARBAZINE
4	Melphalan, carmustine, mechlorethamine, lomustine

Changes to the original scoring system proposed by Drake et al [113] are shown in capital letters.

^aoral continuous treatment (4–6 mg/day) for a month=1 cycle.

Table 4. An improved chemotherapy scoring system [115]

3.8 Strategies of remobilization/ second-line stem cell harvest of patients who fail to achieve minimal progenitor thresholds at the first attempt

After an initial mobilization attempt, if too few CD34+ cells are collected to ensure prompt engraftment, patients often undergo additional mobilization attempts, which increase the risks associated with treatment [116]. Several salvage regimens have been developed to

improve mobilization in patients in whom a first mobilization attempt with G-CSF alone fails to result in collection of an adequate cell dose. In recent years, several investigational agents have been developed that may prove useful for amplifying yields of CD34+ cells without introducing additional toxicity. As the understanding of stem cell interactions with the BM microenvironment grows, new mobilizing agents will emerge.

STRATEGY
second PBSC mobilization using the same regimen
steady-state bone marrow
stimulated BM-“rich bone marrow”
Increase chemotherapy dose: 4-7 g/m ² CTX appears more effective than 2-4 g/m ²
Prolong duration between last chemotherapy and planned collection
Increase growth factor dose (up to 24 µg/kg G-CSF) and use twice daily schedule
Use investigational agents

Table 5. Strategies of remobilization/ second-line stem cell harvest of patients who fail to achieve minimal progenitor thresholds at the first attempt [27,28,117]

Mobilization agent	Mechanism
Cytokines approved for mobilization	
GM-CSF	Stimulates production of granulocytes and macrophages
G-CSF	Granulocyte expansion/activation, protease release and cleavage of adhesion molecules
Chemotherapeutic agents commonly used for mobilization	
CY	Expansion and activation of granulocytes after bone marrow suppression
Paclitaxel	
Etoposide	
Investigational mobilization agents	
Pegylated G-CSF	Granulocyte expansion/activation, protease release and cleavage of adhesion molecules
EPO	Stimulates erythropoiesis
Stem cell factor	G-CSF potentiation
Plerixafor	Disrupts CXCR4/SDF-1 α interactions
SB-251353	GRO-β analog involved in directing the movement of stem cells and other leukocytes
TPO	Regulates megakaryocyte development, G-CSF synergism
Parathyroid hormone	Activates osteoblasts, which produce HGFs in the stem cell niche

Abbreviations: CXCR4=chemokine receptor 4; GRO- β=a human CXC chemokine; SDF-1=stromal cell-derived-factor-1. TPO- thrombopoietin, HGFs- hematopoietic growth factors

Table 6. Mobilization agents currently used in auto-HSCT [27,28,117]

3.8.1 Erythropoietin- EPO

EPO, which is commonly used to preserve blood hemoglobin concentrations in patients undergoing chemotherapy, has also been shown to potentiate the mobilization effect of G-CSF or GM-CSF [118]. Although the mechanism of this cooperative effect is unknown, it is thought that expression of EPO receptors on CD34+ progenitor cells primed with G-CSF or GM-CSF may promote survival of these cells [119]. However, EPO use is generally regarded

as inefficient and, as such, has not become a standard of care. Studies evaluating the mobilization efficacy of EPO plus G-CSF or G-CSF alone in various doses have generated mixed results [120-122]. Further investigation is required to ascertain the clinical benefits of EPO combined with G-CSF [123].

3.8.2 High-dose G-CSF

High-dose G-CSF was investigated as a primary mobilization regimen throughout the 1990s. [49,124,125]. Although seldom used today for primary mobilization, high-dose G-CSF regimens are occasionally used for remobilization [126,127]. Although there is no standard protocol for high-dose G-CSF administration, doses ranging from 16 to 32 µg/kg s.c. daily to 12-16 µg/kg s.c. twice daily have been considered high-dose regimens even though some of the available data apply to patients with aplastic anemia, solid tumors or hematological malignancies other than NHL [124,126,128].

3.8.3 GM-CSF plus G-CSF

Significant synergism has been reported between GM-CSF and G-CSF in the formation of granulocytic colonies in vitro [129]. Mobilization regimens combining GM-CSF with G-CSF have consisted of sequential or concurrent administration of these agents at a range of doses (G-CSF, 5-10 µg/kg; GM-CSF, 5 µg/kg-250 µg/m²), with or without chemotherapeutic agents [130-133]. These combination regimens have not been shown to have substantial benefits over regimens that use G-CSF alone; therefore, GM-CSF and G-CSF are not commonly administered together for primary mobilization. However, the combination of G-CSF and GM-CSF is used as a salvage mobilization regimen when mobilization with G-CSF alone has been unsuccessful [126,134,135].

3.8.4 SCF

The c-kit ligand SCF is produced in BM stromal cells and acts as a potent co-mitogen for many hematopoietic growth factors [32]. Recombinant methionyl human SCF (ancestim, Stemgen, Amgen Inc.) administered sc. in combination with G-CSF has been shown to enhance mobilization and may fasten recovery in transplant recipients [32, 136]. The combination of SCF and G-CSF exerts a sustained mobilization effect that persists longer than does the effect of G-CSF alone, which persists for up to 7 days, as shown by an increase in the numbers of circulating CD34+ cells for up to 13 days in patients with breast cancer (BC) who received the combination treatment [32]. Despite the efficacy of SCF, its use is hindered by the infrequent occurrence of severe anaphylactoid reactions and the resultant need to closely monitor patients after SCF administration [137]. Although approved for use in Canada and New Zealand, ancestim is not currently available in the United States, and it is seldom used in Europe because of the relatively high risk of side effects.

3.8.5 Plerixafor

Plerixafor is a reversible bicyclam inhibitor of hematopoietic stem cells (HSC) binding to SDF-1α on marrow stromal cells via the chemokine receptor 4 (CXCR4) on HSC [138-140]. Plerixafor used in conjunction with G-CSF has been shown in a phase 2 studies to quickly and predictably enhance the numbers of CD34+ cells circulating in the peripheral blood [141]. In patients in whom mobilization with G-CSF either alone or in combination with chemotherapy has previously failed, CD34+ cell yields have been noted to increase by 5- to

100-fold in response to administration of plerixafor plus G-CSF [141,142]. Preliminary results of two phase 3 multicenter randomized placebo-controlled studies indicated that the addition of plerixafor to a G-CSF regimen resulted in greater efficacy than was seen with a regimen of G-CSF alone [140, 143]. In general, treatment with plerixafor and G-CSF was associated with side effects similar to those seen with treatment with G-CSF alone. Most treatment-related AEs appeared to be mild and transient. The most common AEs were gastrointestinal tract effects, such as diarrhea, nausea and vomiting, and injection-site reactions, such as erythema or edema [140, 143].

3.8.6 SB-251353

SB-251353 is another investigational mobilization agent currently in preclinical studies [144,145]. SB-251353 is an analog of GRO- β , a human CXC chemokine involved in directing the movement of stem cells and leukocytes. Although human data are lacking, this agent, when combined with G-CSF in rhesus monkeys, was shown to greatly increase mobilization of stem cells and progenitor cells in comparison with G-CSF alone. Further research is necessary to determine the efficacy and potential toxicities of this treatment in humans. [144,145].

3.8.7 Thrombopoietin- TPO

Endogenous TPO is the primary regulator of megakaryocyte development. Recombinant human TPO (rhTPO) has been shown to act synergistically with G-CSF to enhance stem cell mobilization [146]. This regimen has not been shown to be more efficacious or safer than existing mobilization regimens; however, a few studies document encouraging results [147]. AEs associated with the use of rhTPO plus G-CSF appear to be similar to those seen with the use of G-CSF alone [146,147], however, cytopenias owing to neutralizing antibodies to TPO have been reported in a small number of patients who were given rhTPO to treat chemotherapy-induced thrombocytopenia [148]. Currently, no TPOs have been approved by the FDA for mobilization [149].

3.8.8 Parathyroid hormone

Parathyroid hormone (PTH) activates osteoblasts, which produce hematopoietic growth factors in the stem cell niche, thereby increasing the numbers of circulating stem cells [150,151]. The efficacy and safety of PTH have yet to be established. In a recent phase 1 study, 20 patients with MM, NHL, HD or AML, in whom one or two previous mobilization attempts had failed, received escalating doses of 40, 60, 80 and 100 μ g of PTH (s.c.) for 14 days; PTH doses were combined with G-CSF 10 μ g/kg on the last 4 days of treatment [151]. Overall, 47% of patients in whom one previous mobilization attempt had failed reached the mobilization criterion of >5 CD34 $^{+}$ cells/ μ l in the peripheral blood, and 40% of patients who had previously experienced two failed mobilization attempts reached the mobilization criterion. No dose-limiting toxicity was evident, and PTH was well tolerated; AEs included headache, muscle pain, back pain, fatigue and hypothermia [151].

3.9 BM vs. PBSC for whom? [152]

BM for:

- a. Good risk younger patients
 - Children

- Aplastic anemia, CML in first chronic phase (CP1)
- b. PBSC for:
 - Advanced phase of diseases
 - If graft manipulation is needed
 - Reduced intensity transplants
 - Donor's preference

4. Umbilical cord blood

The use of allogeneic blood and bone marrow stem cell transplantations are limited by the availability of suitably HLA- matched donors. Only 30% of patients have HLA-identical sibling donors and through the National Marrow Donors Program and other registries worldwide nearly 75% of Caucasians, but far fewer racial minorities find suitably HLA-matched donors. In 1988 umbilical cord blood (UCB) hematopoietic stem cells from a related sibling were transplanted successfully into a 5-year-old child with Fanconi anemia. Fifteen years later, this patient is doing well with full donor hematopoietic and lymphoid reconstitution. UCB offers the advantages of easy procurement, no risk to donors, the reduced risk of transmitting infections, immediate availability of cryopreserved units and acceptable partial HLA mismatches. Nearly all patients can find at least one potential 4 of 6 HLA-matched UCB units through either Netcord or other banks. Limited cell dose has been the major limitation to the wide use of UCB for allogeneic transplantation.

The blood in the umbilical cord of newborn babies contains large numbers of stem cells, which have been shown to be capable of long-term engraftment in children and some adults after transplantation. Cord blood cells obtained from the umbilical cord at the time of delivery are used mainly for unrelated allogeneic stem cell transplantation. Patients without time to find an unrelated stem cell donor or who do not have a HLA 10/10 or 9/10 unrelated bone marrow graft donor should be considered for cord blood cells transplantation (CBCT). The cord blood cells may also be used for family- member transplantation, particularly in children for both malignant or nonmalignant diseases [153-155].

Advantages of CBCT compared with bone marrow or mobilized peripheral blood transplantations [156-161] :

- significantly faster graft availability (patients receiving CBCT in a median of 3-5 weeks earlier than those receiving an unrelated bone marrow graft),
- lack of risk to the donor,
- higher frequency of rare haplotypes compared to bone marrow donor registries,
- CD34+/CD38 cord blood cells proliferate more rapidly and generate large number of progenitor cells [162]
- extension of the donor pool due to tolerance of 1-2 HLA mismatches out of 6,
- lower incidence and severity of acute graft-versus-host disease,
- lower risk of infections by latent viruses - such as Epstein-Barr virus or cytomegalovirus

Disadvantages of CBCT compared with bone marrow or mobilized peripheral blood transplantations:

- cell dose is based per kilogram of recipient weight, which can be limiting. Target is $1,7-3,5 \times 10^7$ total nucleated cells/kg,

- low number of hematopoietic progenitor cells- single cord blood unit transplantation (100ml) contains $0,3 \times 10^6$ CD34+ cells/kg (small recipient, below 40kg),
- in adults, single cord blood unit transplantation is associated with very delayed engraftment, combining two products seems to provide more rapid engraftment, albeit at the expense of higher rates of acute graft-versus-host disease,
- donor cannot be used for donor lymphocyte infusion,
- donor cannot be used for treatment of graft rejection or failure.

The cell dose infused is consistently an important marker for improved engraftment and survival. The lower dose of CD34+ cells translate into increased risk of graft failure, delayed hematopoietic engraftment [160] and delayed immune reconstitution [162,163]. Because of the delayed immune reconstitution infections are a serious problem in cord blood transplantation [164].

Many tests have been performed to enhance collection of hematopoietic stem cells in cord blood units. Examples include: in vivo or ex vivo expansion of cord blood cells [165,166], injecting cord blood cells directly into the bone marrow [167], use of double unit CBCT [168,169], use of reduced intensity conditioning regimen [170,171], coinfusion with a haploidentical T cell depleted graft [172,173] or mesenchymal stem cells [174].

5. Storage [1]

Hematopoietic progenitor cell products are stored using various methods depending on the required duration of storage. Products used fresh can be refrigerated for at least 24 hours before infusion. If there is a > 48-hour delay before infusion, most products are frozen to maintain viability. Most frozen products are stored in the vapor phase of liquid nitrogen (< -50 C). Products may be stored for up to 10 years although no longevity limit has yet been determined. Long-term storage is generally done in the liquid phase of liquid nitrogen. Hematopoietic progenitor cells have been frozen using cryoprotectant solutions. The most commonly used cryoprotectant is 10% DMSO and a protein additive such as human serum albumin.

6. References

- [1] Leemhuis T, Sacher RA. Hematopoietic progenitor cells: biology and processing. In: Rossi's principles of transfusion medicine, 4th edn. Simon TL, Snyder EL, Solheim BG, Stowell CP, Strauss RG and Petrides M (eds.). Blackwell Publishing, Singapore, 2009: 508- 520.
- [2] Rashidi HH, Rowley SD. Hematopoietic progenitor cells: autologous transplantation. In: Rossi's principles of transfusion medicine, 4th edn. Simon TL, Snyder EL, Solheim BG, Stowell CP, Strauss RG and Petrides M (eds.). Blackwell Publishing, Singapore, 2009: 521-541.
- [3] Alousi AM, Giralt SA. Hematopoietic progenitor cells: allogeneic transplantation. In: Rossi's principles of transfusion medicine, 4th edn. Simon TL, Snyder EL, Solheim BG, Stowell CP, Strauss RG and Petrides M (eds.). Blackwell Publishing, Singapore, 2009: 542-558.
- [4] Scott D, Donato R, Donato M. Practical Aspects of stem cell collection. In: Hoffman R, Furie B, Benz, E Jr. Hematology: Basic Principles and Practice, Churchill Livingstone, Philadelphia, 2009: 1695-1711.

- [5] Zikos P, Van Lint MT, Frassoni F, et al. Low Transplant Mortality in Allogeneic Bone Marrow Transplantation for Acute Myeloid Leukemia: A Randomized Study of Low-Dose Cyclosporin Versus Low-Dose Cyclosporin and Low-Dose Methotrexate. *Blood* 1998; 91: 3503-3508
- [6] Thomas ED, Storb R. Technique for human marrow grafting. *Blood* 1970; 36: 507-515.
- [7] Brandwein JM, Callum J, Rubinger M, et al: An evaluation of outpatient bone marrow harvesting. *J Clin Oncol* 1989; 7:648-650.
- [8] Confer DL. Hematopoietic Cell Donors. In: Thomas' Hematopoietic Cell Transplantation Third Edition. Blume KG, Forman SJ, Appelbaum FR (red.). Blackwell Publishing; Massachusetts 2004; 538-549
- [9] Buckner CD, Clift RA, Sanders JE, et al: Marrow harvesting from normal donors. *Blood* 1984; 64: 630-634.
- [10] Jin NR, Hill RS, Petersen FB, et al: Marrow harvesting for autologous marrow transplantation. *Exp Hematol* 1985; 13:879-884.
- [11] Stroncek DF, Holland PV, Bartch G, et al: Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program. *Blood* 1993; 81:1940-1946.
- [12] Rowley SD, Donaldson G, Lilleby K, et al: Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. *Blood* 2001; 97:2541-2548.
- [13] Anderlini P, Rizzo JD, Nugent ML, et al. Peripheral blood stem cell donation. An analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. *Bone Marrow Transplant* 2001; 27: 689-692.
- [14] Weisdorf D, Jiller J, Verfaillie C, et al: *Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: A randomized comparison of GM-CSF vs. G-CSF*. *Biol Blood Marrow Transplant* 1997; 3:217-223.
- [15] Gawronski K, Rzepecki P, Oborska S. Hematologic recovery in patients who are treated with autologous stem cells taken from bone marrow after G-CSF stimulation. *EBMT* 2011, Abstr. P1103.
- [16] Lemoli RM, de Vivo A, Damiani D, et al. Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization. *Blood* 2003; 102: 1595-1600.
- [17] Damiani D, Fanin R, Silvestri F, et al. Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients. *Blood* 1997; 90: 36-42.
- [18] al-Fiar F, Prince HM, Imrie K, et al. Bone marrow mononuclear cell count does not predict neutrophil and platelet recovery following autologous bone marrow transplant: value of the colony-forming unit granulocyte-macrophage (CFU-GM) assay. *Cell Transplant* 1997; 6: 491-495.
- [19] Morton J., Hutchins C., Durrant S. Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. *Blood*, 2001, 98, 3186-3191
- [20] Reddy RL. Mobilization and collection of peripheral blood progenitor cells for transplantation. *Transfus Apher Sci* 2005; 32: 63- 72.

- [21] Kessinger A, Armitage JO, Landmark JD, Wisenburger DD. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cell. *Exp Hematol* 1986; 14: 192-196.
- [22] Reiffers J, Bernard P, David B. Successful autologous transplantation with peripheral blood hematopoietic cells in a patient with acute leukemia. *Exp Hematol* 1986; 14: 312-315.
- [23] Kessinger A, Smith DM, Strandford SW, et al. Allogeneic transplantation of blood-derived, T-cell-depleted hematopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. *Bone Marrow Transplant* 1989; 4: 643-646.
- [24] Bensinger WI, Weaver CH, Appelbaum FR, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulated factor. *Blood* 1995; 85: 1655-1658.
- [25] Korbling M, Przepiorka D, YO H, et al. Allogeneic blood cell transplantation for leukemia and lymphoma: potential advantage of blood over marrow allografts. *Blood* 1995; 85: 16590-1665.
- [26] Schmitz N, Dreger P, Suttorp M. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). *Blood* 1995; 85: 1666-1672.
- [27] Reddy RL. Mobilization and collection of peripheral blood progenitor cells for transplantation. *Transfus Apher Sci* 2005; 32: 63- 72.
- [28] Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. *Bone Marrow Transplant* 2009; 43: 181-195.
- [29] Bojko P, Stellberg W, Kudde C, et al. Kinetic study of CD34 cells during peripheral blood stem cecollections. *J Clin Apher* 1999; 14: 18-25.
- [30] Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. *Blood* 1994; 83: 3787-3794.
- [31] Montgomery M, Cottler-Fox M. Mobilization and collection of autologous hematopoietic progenitor/stem cells. *Clin Adv Hematol Oncol* 2007; 5: 127-136.
- [32] Glaspy JA, Shpall EJ, LeMaistre CF, et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. *Blood* 1997; 90: 2939-2951.
- [33] Bensinger W, Singer J, Appelbaum F, et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. *Blood* 1993; 81: 3158-3163.
- [34] Beyer J, Schwella N, Zingsem J, et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. *J Clin Oncol* 1995; 13: 1328-1335.
- [35] Storek J, Gooley T, Siadak M, et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. *Blood* 1997; 90: 4705-4709.
- [36] Champlin R, Schitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. *Blood* 2000; 95: 3702-3709.

- [37] Schrezenmeier H, Passweg JR, Marsh JCW, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA- matched sibling donor transplants for young patients with severe aplastic anemia. *Blood* 2007; 110: 1397-1400.
- [38] Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. *Blood* 1999; 94: 1465-1470.
- [39] Bensinger WI, Clift R, Martin P, et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation. *Blood* 1996; 88: 2794-2800.
- [40] Favre G, Beksac M, Bacigalupo A, et al. Differences between graft product and donor side effects following bone marrow or stem cell donation. *Bone Marrow Transplant* 2003; 32: 873-880.
- [41] Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral- blood cells from HLA-identical relatives in patients with hematologic cancers. *New Engl J Med* 2001; 344: 175-181.
- [42] Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. *Blood* 2002; 100: 761- 767.
- [43] Nervi B, Link DC, DiPersio JF. Cytokines and hematopoietic stem cell mobilization. *J Cell Biochem* 2006; 99: 690-705.
- [44] Winkler IG, Levesque JP. Mechanisms of hematopoietic stem cell mobilization: when innate immunity assails the cells that make blood and bone. *Exp Hematol* 2006; 34: 996-1009.
- [45] Cashen AF, Link D, Devine S, DiPersio J. Cytokines and stem cell mobilization for autologous and allogeneic transplantation. *Curr Hematol Rep* 2004; 3: 406-412.
- [46] Nakamura Y, Tajima F, Ishiga K, et al. Soluble c-kit receptor mobilizes hematopoietic stem cells to peripheral blood in mice. *Exp Hematol* 2004; 32: 390-396.
- [47] Papayannopoulou T, Priestley GV, Nakamoto B, et al. Synergistic mobilization of hematopoietic progenitor cells using concurrent beta1 and beta2 integrin blockade or beta2-deficient mice. *Blood* 2001; 97: 1282-1288.
- [48] Craddock CF, Nakamoto B, Andrews RG, et al. Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. *Blood* 1997; 90: 4779-4788.
- [49] Kobbe G, Sohngen D, Bauser U, et al. Factors influencing G-CSF-mediated mobilization of hematopoietic progenitor cells during steady-state hematopoiesis in patients with malignant lymphoma and multiple myeloma. *Ann Hematol* 1999; 78: 456-462.
- [50] Jacob JF, Suryadevara U, Pereyra V, et al. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature. *Exp Hematol* 2006; 34: 1443-1450.
- [51] Kroger N, Renges H, Kruger W, et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. *Br J Haematol* 2000; 111: 761-765.

- [52] Lord BI, Woolford LB, Molineux G. Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-SCF) or filgrastim SD/01 (PEG-r-metHu G-CSF). *Clin Cancer Res* 2001; 7: 2085-2090.
- [53] Molineux G. The design and development of pegfilgrastim (PEG-rmetHu G-CSF, Neulasta) *Current Pharmaceut Design* 2004; 10: 1235- 1244.
- [54] Kobbe G, Bruns I, Fenk R, et al. Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT. *Bone Marrow Transplant* 2009; 43: 669-677.
- [55] Lee CK, Barlogie B, Munshi N, et al. DT-PACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. *J Clin Oncol* 2003; 21: 2732-2739.
- [56] Tricot G, Barlogie B, Zangari M, et al. Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy. *Haematologica* 2008; 93: 1739-1742.
- [57] Russell N, Mesters R, Schubert J, et al. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. *Haematologica* 2008; 93: 405-412.
- [58] Isidori A, Tani M, Bonifazi F, et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. *Haematologica* 2005; 90: 225-231.
- [59] Nosari A, Cairoli R, Ciapanna D, et al. Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens. *Bone Marrow Transplant* 2006; 38: 413-416.
- [60] Ataergin S, Arpaci F, Turan M, et al. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: A randomized study in patients undergoing autologous peripheral stem cell transplantation. *Am J Hematol* 2008; 83: 644-648.
- [61] Magagnoli M, Spina M, Balzarotti M, et al. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. *Bone Marrow Transplant* 2007; 40: 1019-1025.
- [62] Kopf B, DeGiorgi U, Vertogen B, et al. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization. *Bone Marrow Transplant* 2006; 38: 407-412.
- [63] Gianni AM, Siena S, Bregni M, et al. Granulocyte-macrophage colony stimulating factor to harvest circulating hemopoietic stem cells for autotransplantation. *Lancet* 1989; 2: 580-585.
- [64] Hoeglund M, Smedmyr B, Bengtsson M, et al. Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers- a comparative study. *Eur J Haematol* 1997; 59: 177-183.
- [65] Fu S, Liesveld J. Mobilization of hematopoietic stem cells. *Blood Rev* 2000; 14: 205-218.
- [66] Pavone V, Gaudio F, Guarini A, et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. *Bone Marrow Transplant* 2002; 29: 285-290.
- [67] Watts MJ, Ings SJ, Leverett D, et al. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5g m-2 and G-CSF for pre-

- treated lymphoma patients: a matched pairs analysis of 78 patients. *Br J Cancer* 2000; 82: 278–282.
- [68] Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. *J Clin Oncol* 1999; 17: 3776–3785.
- [69] Alegre A, Tomas JF, Martinez-Chamorro C, et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. *Bone Marrow Transplant* 1997; 20: 211–217.
- [70] Desikan KR, Barlogie B, Jagannath S, et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. *J Clin Oncol* 1998; 16: 1547–1553.
- [71] Narayanasami U, Kanteti R, Morelli J, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. *Blood* 2001; 98: 2059–2064.
- [72] Dazzi C, Cariello A, Rosti G, et al. Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma? *Leuk Lymphoma* 2000; 39: 301–310.
- [73] Condomines M, Quittet P, Lu ZY, Nadal L, Latry P, Lopez E et al. Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor. *J Immunol* 2006; 176: 6631–6639.
- [74] Koumakis G, Vassilomanolakis M, Barbounis V, et al. Optimal timing (preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide. *Oncology* 1999; 56: 28–35.
- [75] Anderlini P, Przepiorka D, Champlin R, Korbling M. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. *Blood* 1996; 88: 2819–2825.
- [76] Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. *Blood* 2008; 111: 1767–1772.
- [77] Pamphilon D, Nacheva E, Navarrete C, et al. The use of granulocyte-colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors. *Transfusion* 2008; 48: 1495–1501.
- [78] Leitner GC, Baumgartner K, Kalhs P, et al. Regeneration, health status and quality of life after rhG-CSF-stimulated stem cell collection in healthy donors: a cross-sectional study.
- [79] Hasenclever D, Sextro M. Safety of alloPBPC donors: biometrical considerations on monitoring long term risks. *Bone Marrow Transplant* 1996; 17 (suppl 2): S28–S30.
- [80] Halter J, Kadera Y, Ispizua UI, et al. Severe events in donors after allogeneic hematopoietic stem cell donation. *Haematologica* 2009; 94: 94–101.
- [81] Martino M, Console G, Dattola A, et al. Short and long-term safety of lenogastim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience. *Bone Marrow Transplant* 2009; 44: 163–168.

- [82] Kuendgen A, Fenk R, Bruns I, et al. Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant* 2006; 38: 69-70.
- [83] Picardi M, De Rosa G, Selleri C, et al. Spleen enlargement following recombinant human granulocyte colony-stimulating factor administration for peripheral blood stem cell mobilization. *Haematologica* 2003; 88: 794-800.
- [84] Anderlini P, Donato M, Chan KW, et al. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the MD Anderson Cancer Center experience. *Transfusion* 1999; 39: 555-560.
- [85] Spiekermann K, Roesler J, Emmendoerffer A, et al. Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications. *Leukemia* 1997; 11: 466-478.
- [86] Ross HJ, Moy LA, Kaplan R, Figlin RA. Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatment. *Cancer* 1991; 68: 441-443.
- [87] Johnson ML, Grimwood RE. Leukocyte colony-stimulating factors. A review of associated neutrophilic dermatoses and vasculitides. *Arch Dermatol* 1994; 130: 77-81.
- [88] Oeda E, Shinohara K, Kamei S, et al. Capillary leak syndrome likely the result of granulocyte-stimulating-factor after high-dose chemotherapy. *Int Med* 1994; 33: 115-19.
- [89] Spitzer T, McAfee S, Poliquin C, Colby C. Acute gouty arthritis following recombinant human granulocyte colony-stimulating factor in an allogeneic blood stem cell donor (letter). *Bone Marrow Transplant* 1998; 21: 966-967.
- [90] Parkkali T, Volin L, Siren MK, Ruutu T. Acute iritis induced by granulocyte colony-stimulating factor used for mobilization in a volunteer unrelated peripheral blood progenitor cell donor. *Bone Marrow Transplant* 1996; 17: 433-434.
- [91] Becker PS, Wagle M, Matous S, et al. Spontaneous splenic rupture following administration of granulocyte colony stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. *Biol Blood Marrow Transplant* 1997; 3: 45-49.
- [92] Adkins DR. Anaphylactoid reaction in a normal donor given granulocyte colony-stimulating factor (letter). *J Clin Oncol* 1998; 16: 812.
- [93] Falzetti F, Aversa F, Minelli O, Tabilio A. Spontaneous rupture of spleen during peripheral blood stem cell mobilization in healthy donor. *Lancet* 1999; 353: 555.
- [94] Hilbe W, Nussbaumer W, Bonatti H, et al. Unusual adverse events following peripheral blood stem cell (PBSC) mobilization using granulocyte colony stimulating factor (G-CSF) in healthy donors. *Bone Marrow Transplant* 2000; 26: 811-813.
- [95] Armitage A, Hargreaves R, Samson D, et al. CD34 counts to predict the adequate collection of peripheral blood progenitor cells. *Bone Marrow Transplant* 1997; 20: 587-591.
- [96] Hill QA, Buxton D, Pearce R, et al. An analysis of the optimal timing of peripheral blood stem cell harvesting following priming with cyclophosphamide and G-CSF. *Bone Marrow Transplant* 2007; 40: 925-930.

- [97] Gandhi MK, Jestice K, Scott MA, et al. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. *Bone Marrow Transplant* 1999; 23: 9-13.
- [98] Villalon L, Odriozola J, Larana JG, et al. Autologous peripheral blood progenitor cell transplantation with $< 2.0 \times 10^6/\text{kg}$: an analysis of variables concerning mobilization and engraftment. *The Hematology Journal* 2000; 1: 374-381.
- [99] Scheid C, Draube A, Reiser M, et al. Using at least $5 \times 10^6/\text{kg}$ CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation. *Bone Marrow Transplant* 1999; 23: 1177-1181.
- [100] Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. *Blood* 1995; 86: 3961-3969.
- [101] Kiss JE, Rybka WB, Winckelstein A, et al. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant* 1997; 19: 303-310.
- [102] Ketterer N, Salles G, Raba M, et al. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. *Blood* 1998; 91: 3148-3155.
- [103] Bolwell BJ, Pohlman B, Rybicki L, et al. Patients mobilizing large numbers of CD34+ cells ("super mobilizers") have improved survival in autologous stem cell transplantation for lymphoid malignancies. *Bone Marrow Transplant* 2007; 40: 437-441.
- [104] Korbling M, Andrelini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? *Blood* 2001; 98: 2900-2908.
- [105] Bacigalupo A, Francesco F, Brinch L, Van Lint MT. Bone marrow or peripheral blood as a source of stem cells for allogeneic transplants. *Curr Opin Hematol* 2000; 7: 343-347.
- [106] Ryncarz RE, Anasetti C. Expression of CD86 on human marrow CD34+ cells identifies immunocompetent committed precursors of macrophages and dendritic cells. *Blood* 1998; 91: 3892-3900.
- [107] Rondelli D, Anasetti C, Fortuna A, et al. T cell alloreactivity induced by normal G-CSF-mobilized CD34+ blood cells. *Bone Marrow Transplant* 1998; 21: 1183-1191.
- [108] Van Rhee F, Jiang YZ, Vigue F, et al. Human G-CSF-mobilized CD34-positive peripheral blood progenitor cells can stimulate allogeneic T-cell responses: implications for graft rejection in mismatched transplantation. *Br J Haematol* 1999; 105: 1014-1024.
- [109] Urbano-Ispizua A, Carreras E, Marin P, et al. Allogeneic transplantation of CD34(+) selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34(+) cells? *Blood* 2001; 98: 2352-2357.
- [110] Mohty M, Bilger K, Jourdan E, et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. *Leukemia* 2003; 17: 869-875.

- [111] Sohn SK, Kim JG, Kim DH, et al. Impact of transplanted CD34+ cell dose in allogeneic unmanipulated peripheral blood stem cell transplantation. *Bone Marrow Transplant* 2003; 31: 967-972.
- [112] Krishnan A, Bhatia S, Slovak M, et al. Predictors for therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. *Blood* 2000; 95: 1588-1593.
- [113] Drake M, Ranaghan L, Morris TCM et al. Analysis of the effect of prior chemotherapy on progenitor cell yield: use of a chemotherapy scoring system. *Br J Haematol* 1997; 98: 745-749.
- [114] Clark RE and Brammer CG. Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system. *Bone Marrow Transplant* 1998; 22: 859-863.
- [115] Jantunen E, Fruehauf S. Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens. *Bone Marrow Transplantation* 2011; 46: 627-635.
- [116] Gazitt Y, Freytes CO, Callender N, et al. Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization. *J Hematother* 1999; 8: 173-183.
- [117] Watts MJ, Ings SJ, Flynn M, et al. Remobilization of patients who fail to achieve minimal progenitor thresholds at the first attempt is clinically worthwhile. *Br J Haematol* 2000; 111: 287-291.
- [118] Olivieri A, Offidani M, Cantori I, et al. Addition of erythropoietin to granulocyte colony-stimulating factor after priming chemotherapy enhances hematopoietic progenitor mobilization. *Bone Marrow Transplant* 1995; 16: 765-770.
- [119] Kaushansky K. Lineage-specific hematopoietic growth factors. *N Engl J Med* 2006; 354: 2034-2045.
- [120] Hart C, Grassinger J, Andreessen R and Hennemann B. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells. *Bone Marrow Transplantation* 2009 43, 197-206.
- [121] Olivieri A, Scortechini I, Capelli D, et al. Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders *Bone Marrow Transplantation* 2004; 34: 693-702.
- [122] Perillo A, Ferrandina G, Pierelli L, et al. Cytokines alone for PBPC collection in patients with advanced gynaecological malignancies: G-CSF vs G-CSF plus EPO. *Bone Marrow Transplant* 2004; 34: 743-744.
- [123] Miller CB, Lazarus HM. Erythropoietin in stem cell transplantation. *Bone Marrow Transplant* 2001; 27: 1011-1016.
- [124] Zeller W, Gutensohn K, Stockschrader M, et al. Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis. *Bone Marrow Transplant* 1996; 17: 709-713.
- [125] Sheridan WP, Begley CG, To LB, et al. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose

- chemotherapy for lymphoid malignancies. *Bone Marrow Transplant* 1994; 14: 105–111.
- [126] Boeve S, Strupeck J, Creech S, et al. Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost. *Bone Marrow Transplant* 2004; 33: 997–1003.
- [127] Wang S, Nademanee A, Qian D, et al. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation. *Transfusion* 2007; 47: 2207–2216.
- [128] Gazitt Y. Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image process, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatment with chemotherapy and anti-lineage-specific antibodies. *Leukemia* 2004; 18: 1–10.
- [129] Bot FJ, van Eijk L, Schipper P, et al. Synergistic effects between GM-CSF and G-CSF or M-CSF on highly enriched human marrow progenitor cells. *Leukemia* 1990; 4: 325–328.
- [130] Gazitt Y. Comparison between granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the mobilization of peripheral blood stem cells. *Curr Opin Hematol* 2002; 9: 190–198.
- [131] Weaver CH, Schulman KA, Wilson-Relyea B, et al. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. *J Clin Oncol* 2000; 18: 43–53.
- [132] Quittet P, Ceballos P, Lopez E, et al. Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m²) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients. *Bone Marrow Transplant* 2006; 38: 275–284.
- [133] Gazitt Y, Callander N, Freytes CO, et al. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study. *J Hematother Stem Cell Res* 2000; 9: 737–748.
- [134] Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. *Biol Blood Marrow Transplant* 2008; 14: 1045–1056.
- [135] Bashey A, Corringham S, Gilpin E, et al. Simultaneous administration of G-CSF and GM-CSF for re-mobilization in patients with inadequate initial progenitor cell collections for autologous transplantation. *Cytotherapy* 2000; 2: 195–200.
- [136] Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. *Exp Hematol* 2002; 30: 973–981.
- [137] Costa JJ, Demetri GD, Harrist TJ, et al. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. *J Exp Med* 1996; 183: 2681–2686.
- [138] Stiff P, Micallef I, McCarthy P, et al. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral

- blood stem cells when given a mobilizing regimen of G-CSF: Implications for the heavily pretreated patient. *Biol Blood Marrow transplant* 2009; 15: 249-256.
- [139] Fowkler CJ, Dunn A, Hayes-Lattin B, et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. *Bone Marrow Transplant* 2009; 43: 909-917.
- [140] DiPersio J, Stadtmauer EA, Nademanee AP, et al. A phase III, multicenter, randomized, double-blind, placebo controlled, comparative trial of AMD3100 (plerixafor)+G-CSF vs G-CSF+placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation. *Blood (ASH Annual Meeting Abstracts)* 2007; 110: 445.
- [141] Flomenberg N, Devine SM, DiPersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. *Blood* 2005; 106: 1867-1874.
- [142] Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. *Bone Marrow Transplant* 2008; 41: 331-338.
- [143] DiPersio JF, Micallef I, Stiff PJ, et al. A phase III, multicenter, randomized, double-blind, placebo controlled, comparative trial of AMD3100 (plerixafor)+G-CSF vs. placebo+G-CSF in non-Hodgkin's lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. *Blood (ASH Annual Meeting Abstracts)* 2007; 110: 601.
- [144] King AG, Horowitz D, Dillon SB, et al. Rapid mobilization of murine hematopoietic stem cells with enhanced engraftment properties and evaluation of hematopoietic progenitor cell mobilization in rhesus monkeys by a single injection of SB-251353, a specific truncated form of the human CXC chemokine GRObeta. *Blood* 2001; 97: 1534-1542.
- [145] Pelus LM, Fukuda S. Peripheral blood stem cell mobilization: the CXCR2 ligand GRObeta rapidly mobilizes hematopoietic stem cells with enhanced engraftment properties. *Exp Hematol* 2006; 34: 1010-1020.
- [146] Somlo G, Sniecinski I, ter Veer A, et al. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. *Blood* 1999; 93: 2798-2806.
- [147] Linker C, Anderlini P, Herzig R, et al. Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation. *Biol Blood Marrow Transplant* 2003; 9: 405-413.
- [148] Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. *Blood* 2001; 98: 3241-3248. Bassar RL, O'Flaherty E, Green M, Edmonds M, Nichol J, Menchaca DM et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. *Blood* 2002; 99: 2599-2602.

- [149] Basser R. The impact of thrombopoietin on clinical practice. *Curr Pharm Des* 2002; 8: 369–377.
- [150] Adams GB, Martin RP, Alley IR, et al. Therapeutic targeting of a stem cell niche. *Nat Biotechnol* 2007; 25: 238–243.
- [151] Ballen KK, Shpall EJ, Avigan D, et al. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. *Biol Blood Marrow Transplant* 2007; 13: 838–843.
- [152] Ispizua Urbano A. Stem cell product for allo-SCT. Tenth ESH-EBMT training course on haematopoietic stem cell transplantation. Warsaw, Poland 2006.
- [153] Wagner JE, Kernan NA, Steinbuch M, et al. Allogeneic sibling umbilical cord-blood transplantation in children with malignant and non-malignant disease. *Lancet* 1995; 346: 214–219.
- [154] Rocha V, Kabbara N, Ionescu et al. Pediatric related and unrelated cord blood transplantation for malignant diseases. *Bone Marrow Transplant* 2009; 44: 653–659.
- [155] Rocha V, Locatelli F. Searching for alternative hematopoietic stem cell donors for pediatric patients. *Bone Marrow Transplant* 2008; 41: 207–214.
- [156] Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukaemia. *Blood* 2001; 97: 2962–2971.
- [157] Rocha V, Wagner JE, Jr., Sobocinski KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. *N Engl J Med* 2000; 342: 1846–1854.
- [158] Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. *N Engl J Med* 2004; 351: 2276–2285.
- [159] Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. *Lancet* 2007; 369: 1947–1954.
- [160] Laughlin M, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukaemia. *N Engl J Med* 2004; 351: 2265–2275.
- [161] Niehues T, Rocha V, Filipovich AH, et al. Factors affecting lymphocyte subset reconstitution after either related or unrelated cord blood transplantation in children- a Eurocord analysis. *Br J Haematol* 2001; 114: 42–48.
- [162] Hao QL, Shah AJ, Thiemann FT, et al. A functional comparison of CD34+ CD38- cells in cord blood and bone marrow. *Blood* 1995; 86: 3745–3753.
- [163] Komanduri KV, St John LS, De Lima M, et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. *Blood* 2007; 110: 4543–4551.
- [164] Saavedra S, Sanz GF, Jarque I, et al. Early infections in adult patients undergoing unrelated donor cord blood transplantation. *Bone Marrow Transplant* 2002; 30: 937–943.
- [165] Delaney C, Varnum-Finney B, Aoyama K, et al. Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells. *Blood*. 2005; 106: 2693–2699.

- [166] de Lima M, McMannis J, Gee A, et al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. *Bone Marrow Transplant* 2008;41: 771–778.
- [167] Frassoni F, Gualandi F, Podestà M, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. *Lancet Oncol* 2008; 9: 831–839.
- [168] Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. *Blood*. 2005; 105: 1343–1347.
- [169] Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. *Blood*. 2007; 110: 3064–3070.
- [170] Barker JN, Weisdorf DJ, DeFor TE, et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. *Blood*. 2003; 102: 1915–1919.
- [171] Ballen KK, Spitzer TR, Yeap BY, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. *Biol Blood Marrow Transplant* 2007; 13: 82–89.
- [172] Fernandes J, Rocha V, Robin M, et al. Second transplant with two unrelated cord blood units for early graft failure after haematopoietic stem cell transplantation. *Br J Haematol* 2007; 137: 248–251.
- [173] Bautista G, Cabrera JR, Regidor C, et al. Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor. *Bone Marrow Transplant* 2009; 43: 365–373.
- [174] MacMillan ML, Blazar BR, DeFor TE, et al. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. *Bone Marrow Transplant*. 2009; 43: 447–454.

IntechOpen

New Advances in Stem Cell Transplantation

Edited by Prof. Taner Demirer

ISBN 978-953-51-0013-3

Hard cover, 582 pages

Publisher InTech

Published online 24, February, 2012

Published in print edition February, 2012

This book documents the increased number of stem cell-related research, clinical applications, and views for the future. The book covers a wide range of issues in cell-based therapy and regenerative medicine, and includes clinical and preclinical chapters from the respected authors involved with stem cell studies and research from around the world. It complements and extends the basics of stem cell physiology, hematopoietic stem cells, issues related to clinical problems, tissue typing, cryopreservation, dendritic cells, mesenchymal cells, neuroscience, endovascular cells and other tissues. In addition, tissue engineering that employs novel methods with stem cells is explored. Clearly, the continued use of biomedical engineering will depend heavily on stem cells, and this book is well positioned to provide comprehensive coverage of these developments.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Piotr Rzepecki, Sylwia Oborska and Krzysztof Gawroński (2012). Sources of Hematopoietic Stem Cells, New Advances in Stem Cell Transplantation, Prof. Taner Demirer (Ed.), ISBN: 978-953-51-0013-3, InTech, Available from: <http://www.intechopen.com/books/new-advances-in-stem-cell-transplantation/sources-of-hematopoietic-stem-cells>

INTeCH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen